Three Therapeutic Strategies: Cinacalcet, Paricalcitol or Both in Secondary Hyperparathyroidism Treatment in Hemodialysed Patients During 1-Year Observational Study-A Comparison

Frontiers in Endocrinology
Jacek ZawieruchaTeresa Dryl-Rydzyńska

Abstract

Introduction: Secondary hyperparathyroidism (sHPT) is a common hormonal complication of chronic kidney disease. There are several therapeutic options for sHPT management aiming at calcium-phosphorus balance normalization and decrease of parathormone secretion. Objectives: The aim of this retrospective, observational study was the outcome assessement of three most common therapeutic strategies of secondary hyperparathyroidism treatment with vitamin D receptor activator-paricalcitol, calcimimetic-cinacalcet or both agents administered together during in 12-months period. Methods: One hundred and thirty-one haemodialysed patients with uncontrolled parathyroid hormone secretion have been treated with paricalcitol administered intravenously (group PAR-60 patients) or cinacalcet per os (group CIN-50 patients). The last group (group PAR+CIN-21 patients) received paricalcitol i.v. and oral cinacalcet administered simultaneously. Results: In all groups, the iPTH level decreased significantly, however in group 1 treated with paricalcitol administered intravenously iPTH level decrease was greater than in group 2 treated with cinacalcet and in group 3 treated with paricalcitol and cinacalcet in parallel. The most substantial change of iPTH...Continue Reading

References

Nov 2, 2001·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·F Llach, M Yudd
Feb 22, 2003·Journal of the American Society of Nephrology : JASN·L Darryl QuarlesDavid A Bushinsky
Apr 9, 2004·The New England Journal of Medicine·Geoffrey A BlockWilliam G Goodman
Aug 21, 2007·Clinical Journal of the American Society of Nephrology : CJASN·Glenn M ChertowUNKNOWN CONTROL Investigators
Aug 25, 2007·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·Masafumi FukagawaUNKNOWN KRN1493 study group
Mar 4, 2008·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·Geoffrey A BlockUNKNOWN TARGET Investigators
Aug 1, 2009·Kidney International. Supplement·UNKNOWN Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group
Sep 8, 2009·Journal of the American Board of Family Medicine : JABFM·Wissam Saliba, Boutros El-Haddad
Nov 3, 2010·Kidney International. Supplement·Neal MittmanMorrell M Avram
Sep 21, 2011·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·Markus KettelerPaul Audhya
Mar 6, 2012·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·Markus KettelerSamina Khan
Apr 24, 2012·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·Mario CozzolinoUNKNOWN FARO Study Group
Jun 12, 2012·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·Andrzej T SlominskiRobert C Tuckey
Oct 3, 2012·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·Pablo A Ureña-TorresPaolo Raggi
Nov 6, 2012·The New England Journal of Medicine·UNKNOWN EVOLVE Trial InvestigatorsPatrick S Parfrey
Nov 29, 2012·BMC Nephrology·María Jesús IzquierdoPedro Abaigar
Mar 8, 2013·American Journal of Nephrology·Flore DurantonAngel Argilés
Oct 11, 2013·The Journal of Clinical Endocrinology and Metabolism·Patrick S ParfreyWilliam G Goodman
Feb 7, 2014·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·Mario CozzolinoSamina Khan
Jun 22, 2014·Arteriosclerosis, Thrombosis, and Vascular Biology·Claudia GoettschElena Aikawa
Dec 3, 2014·The Journal of Steroid Biochemistry and Molecular Biology·Andrzej T SlominskiRobert C Tuckey
Dec 17, 2014·Journal of the American Society of Nephrology : JASN·Sharon M MoeUNKNOWN Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) Trial Investigators
Feb 25, 2015·Clinical Journal of the American Society of Nephrology : CJASN·Patrick S ParfreyUNKNOWN Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) Trial Investigators
Apr 18, 2015·BMC Nephrology·Piergiorgio MessaUNKNOWN FARO Study Group
Aug 1, 2009·Kidney International·Kai-Uwe Eckardt, Bertram L Kasiske
Dec 13, 2016·Clinical Journal of the American Society of Nephrology : CJASN·Andreas PaschJuergen Floege
Oct 27, 2017·Polish Archives of Internal Medicine·Jacek ZawieruchaTeresa Dryl-Rydzyńska

❮ Previous
Next ❯

Citations

Feb 18, 2020·Canadian Association of Radiologists Journal = Journal L'Association Canadienne Des Radiologistes·Allison Herring, Derik L Davis

❮ Previous
Next ❯

Software Mentioned

EVOLVE
ADVANCE

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.